Recombinant bicistronic flaviviruses and methods of use thereof

Details Recombinant bicistronic flaviviruses and methods of use thereof Recombinant bicistronic flaviviruses and methods of use thereof

2011-01-18

2011-01-18

Li, Bao (Department: 1648)

Chemistry: molecular biology and microbiology

Vector, per se

C424S218100

Reexamination Certificate

active

07871814

ABSTRACT:
The present invention provides recombinant bicistronic flaviviruses, particularly live attenuated recombinant bicistronic flavivirus, which comprise, in order from 5′ to 3′, a viral 5′UTR, an ORF encoding all viral proteins, an internal ribosome entry site, an exogenous nucleotide sequence that encodes an exogenous polypeptide, and a viral 3′UTR. Infection of a host cell with a recombinant flavivirus provides for expression of the exogenous nucleic acid in a host cell. Such recombinant flavivirus are useful for delivering a protein to a mammalian host; and for eliciting an immune response to the exogenous polypeptide.

REFERENCES:
patent: 6392028 (2002-05-01), Rice et al.
patent: 6893866 (2005-05-01), Westaway et al.
patent: WO 99/28487 (1998-11-01), None
Khromykh, A. et al. Subgenomic Replicons of the Flavivirus Kunjin: Construction and Applications (1997) Journal of Virology, 71(2): 1497-1505.
Forns, X. et al. Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute reolving or persistent infection in chimpanzees (2002) Pro. Natl. Acad. Sci. 97(24):13318-13323.
Monath, T.P. et al. Recombinant, chimaeric live, attenuated vaccine (ChimeriVaxTM) incorporating the envelope genes of Japanese encephalitis (Sa 14-14-2) virus . . . (1999) Vaccine 17:1869-1882.
Lionnet et al. Protein Expression and Purification 2001, vol. 21, pp. 492-499.
Fillippis et al. J. Medical Virol. 2002, vol. 68, pp. 620-627.
Guirahoo et al. Virol. 1999, vol. 257, pp. 363-372.
Chambers et al. J. Virol. 1999, vol. 73, No. 4, pp. 3095-3101.
Lee et al. J. Virol. 2000, vol. 74, No. 1. pp. 24-32.
The Lancet 2001, vol. 358, pp. 121-122.
Ryman et al. Virol. 1998, vol. 244, pp. 59-65.
Proutiski et al. Virus Research 1999, vol. 64, pp. 107-123.
Worrow et al. The case law aboutKSR International Co. v.Teleflex Inc.—Conclude that Ordinary Innovation is Obviou, Published in 2007, in Website: www.fewick.com, pp. 1-2.
Charles et al. Journal of Bacterialogy 1958, vol. 164, No. 1, pp. 123-129.
Jin et al. Genetics 2005vol. 42, pp. 207-209.
McAllister, A. et al., Recombinant yellow fever viruses are affective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases, Oct. 2000. Journal of Virology, vol. 74, No. 19, pp. 9197-9205.
Qu, L., et al., Isolation and characterization of noncytopathic pestivirus mutants reveals role for nonstructural protein NS4B in viral cytopathogenicity, Nov. 2001, Journal of Virology, vol. 75, No. 22, 10651-10662.
Alexander, L. et al., Dicistronic Poliovirus as Expression Vectors for Foreign Genes, 1994, Aids Research and Human Retroviruses, vol. 10, Supplement 2, S57-S60.

Affiliated with

Also associated with

Rating

Recombinant bicistronic flaviviruses and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Recombinant bicistronic flaviviruses and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant bicistronic flaviviruses and methods of use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2619013